ADVERTISEMENT
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

X-Linked Retinitis Pigmentosa (XLRP) Epidemiology Forecast to 2030 - ResearchAndMarkets.com

September 21, 2021 GMT

DUBLIN--(BUSINESS WIRE)--Sep 21, 2021--

The “X-Linked Retinitis Pigmentosa (XLRP) - Epidemiology Forecast - 2030” drug pipelines has been added to ResearchAndMarkets.com’s offering.

The ‘X-Linked Retinitis Pigmentosa (XLRP) - Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted X-Linked Retinitis Pigmentosa (XLRP) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

X-Linked Retinitis Pigmentosa (XLRP) Epidemiology Perspective

The X-Linked Retinitis Pigmentosa (XLRP) epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The X-Linked Retinitis Pigmentosa (XLRP) epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM.

ADVERTISEMENT

The X-Linked Retinitis Pigmentosa (XLRP) epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2017 to 2030. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

X-Linked Retinitis Pigmentosa (XLRP) Detailed Epidemiology Segmentation

The X-Linked Retinitis Pigmentosa (XLRP) epidemiology covered in the report provides historical as well as forecasted X-Linked Retinitis Pigmentosa (XLRP) epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom) and Japan from 2017 to 2030.

The X-Linked Retinitis Pigmentosa (XLRP) report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

Key Questions Answered

ADVERTISEMENT

  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to X-Linked Retinitis Pigmentosa (XLRP)?
  • What are the key findings pertaining to the X-Linked Retinitis Pigmentosa (XLRP) epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2017-2030)?
  • What would be the total number of patients of X-Linked Retinitis Pigmentosa (XLRP) across the 7MM during the forecast period (2017-2030)?
  • Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017-2030)?
  • At what CAGR the patient population is expected to grow in 7MM during the forecast period (2017-2030)?
  • What is the disease risk, burden and unmet needs of the X-Linked Retinitis Pigmentosa (XLRP)?
  • What are the currently available treatments of X-Linked Retinitis Pigmentosa (XLRP)?

Key Topics Covered:

1. Key Insights

2. Executive Summary of X-Linked Retinitis Pigmentosa (XLRP)

3. X-Linked Retinitis Pigmentosa (XLRP): Disease Background and Overview

3.1. Introduction

3.2. Sign and Symptoms

3.3. Pathophysiology

3.4. Risk Factors

3.5. Diagnosis

4. Patient Journey

5. Epidemiology and Patient Population

5.1. Epidemiology Key Findings

5.2. Assumptions and Rationale: 7MM

5.3. Epidemiology Scenario: 7MM

5.4. United States Epidemiology

5.5. EU-5 Country-wise Epidemiology

5.5.1. Germany Epidemiology

5.5.2. France Epidemiology

5.5.3. Italy Epidemiology

5.5.4. Spain Epidemiology

5.5.5. United Kingdom Epidemiology

5.6. Japan Epidemiology

6. Treatment Algorithm, Current Treatment, and Medical Practices

6.1. X-Linked Retinitis Pigmentosa (XLRP) Treatment and Management

6.2. X-Linked Retinitis Pigmentosa (XLRP) Treatment Algorithm

7. KOL Views

8. Unmet Needs

9. Appendix

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/lma01c

View source version on businesswire.com:https://www.businesswire.com/news/home/20210921005866/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2021.

PUB: 09/21/2021 11:32 AM/DISC: 09/21/2021 11:32 AM

http://www.businesswire.com/news/home/20210921005866/en